



December 5, 2024

FOR IMMEDIATE RELEASE

Company name	Resorttrust, Inc.
Representative	Ariyoshi Fushimi, President
Code	4681, Prime of Tokyo Stock Exchange and Premier of Nagoya Stock Exchanges

CICS, a Consolidated Subsidiary of Resorttrust, Inc., Completes a 90-Day Observation Period for the Primary Evaluation of the Domestic Phase II Clinical Trial of BNCT Targeting Angiosarcoma

We are pleased to announce that the 90-day observation period for the primary evaluation of the domestic Phase II clinical trial of boron neutron capture therapy (BNCT) targeting angiosarcoma has been successfully completed. This trial is being conducted by Cancer Intelligence Care Systems, Inc. (hereinafter “CICS”); President: Tetsuya Furukawa, Headquarters: Koto-ku, Tokyo; a consolidated subsidiary of Resorttrust, Inc.) and Stella Pharma Corporation (President & COO: Koki Uehara, Headquarters: Chuo-ku, Osaka).

The trial aims to evaluate the efficacy of BNCT using CICS’s neutron irradiation device (CICS-1) and Stella Pharma’s boron drug (SPM-011) in patients with inoperable angiosarcoma. Conducted as a single-arm trial with 10 participants at the National Cancer Center Hospital, the study focuses on patients with locally advanced or recurrent disease who have limited treatment options, including those for whom chemotherapy and radiotherapy are not viable.

After carefully assessing the results of the evaluation and data analysis of the upcoming main trial, CICS will aim to commercialize the neutron irradiation device by 2026. The impact that the completion of the clinical trial will have on Resorttrust’s consolidated financial results for the current fiscal year is expected to be minimal.

The Resorttrust Group entered the medical business in 1994, beginning its membership-based medical club. For cancer screening, the Group introduced positron emission tomography (PET), which at the time was used for research conducted at Yamanakako Clinic. In addition to greatly contributing to the spread of PET in Japan, it has helped to promote research activities with university hospitals in fields such as image diagnosis and preemptive medicine. Today, the Resorttrust Group is not only involved in screening but is also expanding treatment solutions, supporting the operation of facilities providing advanced cancer immunotherapy.

Based on the brand identity of “Together for a Wonderful Life” the Resorttrust Group has as its slogan “contributing to the age of 100-year life spans (wellbeing).” Furthermore, reflecting the Group’s hope to create a society where cancer claims no precious lives, it has engaged in cancer screening and treatment. Through our initiatives with BNCT, together with helping to create a more affluent, happy time, we hope to bring new light to cancer treatment.

*1: About angiosarcoma

Angiosarcoma is a type of cancer that originates from the endothelial cells of blood vessels. It can develop anywhere in the body, but it most commonly appears in the skin. This rare and highly malignant form of cancer currently lacks an established effective treatment.

*2: Single-arm trial

A single-arm trial is a study in which all participants receive the same treatment.

About BNCT

Boron neutron capture therapy (BNCT), a form of radiotherapy, is a new method of treating cancer.

When patients receive a boron agent, a boron compound (^{10}B) accumulates in their cancer cells. The area of the tumor is then exposed to an external source of extremely low-energy neutron radiation, which while having little effect on the human body, causes the boron (^{10}B) to capture neutrons, resulting in a reaction that causes the release of alpha rays and ^7Li nuclei. BNCT is therefore a medical treatment that leverages radiation to selectively kill cancer cells.

In addition, in principle, as treatment is completed with a single neutron irradiation, expectations are for this to be a treatment that causes little damage to the body.

About the CICS neutron capture therapy device

This is an accelerator-based neutron capture therapy device developed by CICS. It produces neutrons by bombarding a lithium target with protons which are accelerated by a Radio Frequency Quadrupole (RFQ) linear accelerator. CICS-1 is notable for the low level of contamination of fast neutrons, which are detrimental to the human body. The neutrons produced have a low energy level of 800keV or less, facilitating the miniaturization of the moderator used to slow the neutrons down to around 10keV, a level suitable for BNCT.